RTI Announces 2009 Fourth Quarter and Year End Earnings and Conference Call

01/20/2010

• Wendy Crites Wacker, APR
• Director, Corporate Communications
• wwacker@rtix.com
• 386-418-8888 (4220)

RTI BIOLOGICS ANNOUNCES 2009 FOURTH QUARTER AND YEAR END EARNINGS AND CONFERENCE CALL
*Company Will Outline 2010 Guidance During Conference Call*

ALACHUA, Fla. (Jan. 20, 2010) – RTI Biologics Inc. (RTI) (Nasdaq: RTIX), the Florida-based processor of orthopedic, dental, hernia and other biologic implants, will be releasing financial results from the 2009 fourth quarter and year end on Tuesday, Feb. 9, 2010 before the market opens. The company will also outline financial guidance for the full year 2010.

RTI will hold a live conference call and simultaneous audio Web cast on Tuesday, Feb. 9, 2010 at 9:00 a.m. ET to discuss the 2009 fourth quarter and year end results, as well as guidance for 2010. The conference call can be accessed by dialing (888) 500-6974. The Web cast can be accessed through the investor section of RTI’s Web site at www.rtix.com. A telephone replay of the call will be available through March 1, 2010 and can be accessed by calling (888) 203-1112, passcode 6416137; the replay will also be available at www.rtix.com.

About RTI Biologics Inc.

RTI Biologics Inc. is a leading provider of sterile biological implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening, precision shaping and proprietary, validated sterilization processes. These allograft and xenograft implants are used in orthopedic, dental, hernia and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of more than two million implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to penetrate tissue, inactivate or remove viruses and a wide range of organisms using worst-case testing and maintain tissue biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Neunkirchen, Germany, and Aix-en-Provence, France. The company is accredited in the U.S. by the American Association of Tissue Banks.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the Securities and Exchange Commissions (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s Web site at www.rtix.com or the SEC’s Web site at www.sec.gov.

###